Endocrine Abstracts

Introduction: New treatments of diabetes improve global metabolic status beyond glycemic control and achieve weight reduction in many patients.

Case reports: We described four case reports to show GLP-1 agonists and dapaglifozin effects on metabolism and weight in patients with type 2 diabetes and obesity.

Case 1 (Liraglutide): A 48-year-old man, hypertension, type 2 diabetes and extreme obesity. Baseline visit: treatment enalapril 20, acetylsalicylic acid 100, metformin 850. Weight 191 kg, BMI 60.9 and HbA1c 6.6%. After 4 months under treatment with liraglutide: weight 158 kg, BMI 50.4 and HbA1c 5.3%.

Case 2 (Exenatide lar): A 58-year-old man, type 2 diabetes and extreme obesity. Baseline visit: weight 141 kg, BMI 50 and HbA1c 6.7%. After 4 months under treatment with metformin 850 and exenatide lar: weight 133 kg, BMI 47 and HbA1c 6%. After 10 months under treatment with metformin 850 and exenatide lar: weight 127 kg, BMI 44.9 and HbA1c 5.5%.

Case 3 (Lixisenatide): A 52-year-old woman, hypertension, type 2 diabetes and extreme obesity. Baseline visit: treatment metformin 850, simvastatin 20, losartan 100, atenolol 50. Weight 138 kg, BMI 55.4 and HbA1c 9%. After 4 months under treatment with metformin 850 and lixisenatide: weight 133 kg, BMI 47 and HbA1c 6%. After 10 months under treatment with metformin 850 and lixisenatide: weight 125 kg, BMI 48.8 and HbA1c 5.7%.

Case 4 (Dapaglifozin): A 64-year-old man, type 2 diabetes, dyslipidaemia and grade 1 obesity. Baseline visit: treatment metformin 850 and simvastatin 40. Weight 106 kg, BMI 34.2 and HbA1c 8.8%. After 5 months under treatment with dapaglifozin: weight 93.6 kg, BMI 31.8 and HbA1c 6.6%.

Conclusion: GLP-1 agonists and dapaglifozin got ssignificant improvement of anthropometric parameters and glycaemic control in patients with type 2 diabetes and obesity. They were safety and well tolerated, and could represent a promising alternative to bariatric surgery.